Company news

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news

Vertex Pharmaceuticals Incorporated news releases on 6ix. Latest, Sep 22, 2026: Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin…

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news

Press releases & updates

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

Vertex to Present at the Goldman Sachs Communacopia + Technology Conference

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)

Vertex Reports Second Quarter 2026 Financial Results

Vertex to Announce Second Quarter 2026 Financial Results on Monday, August 3, 2026

Cystic Fibrosis Market, Global & Regional Now Available; Profiles Vertex Pharmaceuticals, AbbVie, and Other Frontrunner Competitors in Orphan Drug Markets

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults

Vertex to Participate in Upcoming May Investor Conferences

Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)

Vertex Reports First Quarter 2026 Financial Results

Vortex Energy Announces Intent to Advance Next Phase of Technical Work at the Robinsons River Salt Project and Engages Lonquist

A Call to Action to Help Fight Kidney Failure in At-Risk Communities: American Kidney Fund Urges People to be APOL1 Aware

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Vertex to Announce First Quarter 2026 Financial Results on May 4th

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

Vortex Energy Announces Postponement of AGM

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

Vortex Energy Highlights 2025 Technical Milestones Across Project Portfolio and Announces Adjournment of AGM to February 13, 2026

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention

Vertex Reports Third Quarter 2025 Financial Results

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Vertex Announces Key Advancements Across Kidney Portfolio